Daniel P. O’Day
Chairman and Chief Executive Officer
Executive
7 yr
4 reports
Gilead Sciences, Inc. ·GILD
Commercial and medical leaders dominate the CEO’s span
Health Care · Fortune #149 · Divisional structure · 18K employees · Foster City, CA
View as of:
3
CEO span
↓ tighter than peers (avg 9)
1.3
Avg span
tight
3
Max depth
3 levels
5 yr
Avg tenure
↓ 1.0yr from FY2024
0%
Internal hires
↓ below industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$29.4B
Operating income
$10.0B
Net income
$8.5B
Total assets
$59.0B
Shares out
1.24B
Sourced from Gilead Sciences, Inc. DEF 14A · filed 2026-03-20 ↗ View on SEC
Interactive org chart
Gilead Sciences, Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Commercial and medical leaders dominate the CEO’s span at Gilead Sciences, with no COO layer. This page maps the executive structure, profiles named leaders, reviews recent leadership changes, and compares Gilead’s lean C-suite with large biopharma peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Deborah H. Telman departed as EVP, Corporate Affairs and General Counsel
Departed effective December 5, 2025.
Source · See change logScenario views in the chart
- Add Chief Operating Officer Introduce a COO reporting to the CEO to consolidate operations and manufacturing oversight.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
4 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
Andrew D. Dickinson
Chief Financial Officer
Finance
6 yr
1 reports
Johanna Mercier
Chief Commercial and Corporate Affairs Officer
Commercial
6 yr
0 reports
Dietmar Berger
Chief Medical Officer
Medical Affairs
1 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 1 named executive officers disclosed. Bar length scales with total compensation.
Daniel P. O’Day $28.4M
- Base salary
- $1.80M
- Bonus
- $15.24M
- Stock awards
- $4.50M
- Option awards
- $4.85M
- Non-equity incentive
- $2.06M
- Other
- $2.06M
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The skin in the game
Beneficial ownership
Insider stock holdings and the company's ownership requirements for executives and directors. Disclosed in the most recent DEF 14A.
Stock ownership requirements
5×Director cash retainer
Directors must hold shares equal to five times annual cash retainer.
| Holder | Shares | % of class |
|---|---|---|
| Daniel P. O’Day | 1.97M | <1% |
The businesses
How Gilead Sciences, Inc. divides the work
3 divisions report into the group CEO. Tile size scales with estimated headcount.
Finance
800 employees
Chief Financial Officer (Andrew D. Dickinson)
Oversees financial planning, reporting, treasury, tax and investor relations.
Commercial & Corporate Affairs
6K employees
Chief Commercial and Corporate Affairs Officer (Johanna Mercier)
Leads global sales, marketing, public affairs and corporate communications.
Medical Affairs
1K employees
Chief Medical Officer (Dietmar Berger)
Responsible for clinical development, medical strategy and patient safety.
The thesis
Why this org is unusual
Commercial and medical leadership roles account for most of the CEO’s direct oversight, an unusual concentration for a large-cap biopharma.
The CEO directly manages finance, commercial/corporate affairs, and medical affairs without an intervening COO layer. This keeps product commercialization and clinical strategy close to the top but also concentrates decision-making at the CEO level.
The absence of a COO or separate R&D president highlights Gilead’s reliance on functional depth rather than layered operating control. Finance retains a traditional structure under the CFO, with controllership explicitly elevated following recent accounting leadership changes.
- No COO role
- Medical and commercial leaders report directly to CEO
The comparison
How Gilead Sciences, Inc. stacks up
Compared with peers like Pfizer and Merck, Gilead operates with a smaller C-suite and fewer layers between the CEO and core functions. Many peers separate commercial, R&D, and operations into semi-autonomous groups led by presidents or COOs. Gilead’s flatter executive span reflects its focused therapeutic portfolio …
C-suite size
Reporting depth
Gilead Sciences, Inc.
3 levels
5 levels
5 levels
5 levels
4 levels
Avg C-suite tenure
Has COO / Has CAIO
Gilead Sciences, Inc. — no COO — no CAIO
Current signals
What changed recently
The most significant change was the December 2025 departure of General Counsel Deborah Telman.
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-03-20
- CEO
- Daniel P. O’Day
- CEO span
- 3
- C-suite
- 5
- Avg tenure
- 5 yr
Transition year marked by General Counsel departure.
Named executive officers (5)
- Daniel P. O’Day - CEO since 2019
- Andrew D. Dickinson - CFO since 2020
- Johanna Mercier - CCO since 2019
- Dietmar Berger - CMO since 2025
- Deborah H. Telman - EVP & General Counsel since 2022
FY2024
DEF 14A filed 2025-03-21
- CEO
- Daniel P. O’Day
- CEO span
- 4
- C-suite
- 5
- Avg tenure
- 6 yr
Stable executive team prior to 2025 changes.
Named executive officers (4)
- Daniel P. O’Day - CEO since 2019
- Andrew D. Dickinson - CFO since 2020
- Johanna Mercier - CCO since 2019
- Deborah H. Telman - EVP & General Counsel since 2022
FY2023
DEF 14A filed 2024-03-22
- CEO
- Daniel P. O’Day
- CEO span
- 4
- C-suite
- 5
- Avg tenure
- 6 yr
Commercial leadership firmly established under CEO.
Named executive officers (3)
- Daniel P. O’Day - CEO since 2019
- Andrew D. Dickinson - CFO since 2020
- Johanna Mercier - CCO since 2019
Year-over-year changes
Loss of the General Counsel role reduced the CEO’s direct span.
- CEO span: 4 → 3
- C-suite size: 5 → 5
- Avg tenure: 6 → 5 yr
- departed Deborah H. Telman - EVP & General Counsel (was EVP & General Counsel) (DEF 14A 2026-03-20)
The board
Board of directors
2 directors. 1 of 2 independent (50%). Source: most recent DEF 14A.
Daniel P. O’Day
Chair Inside
Chairman and CEO, Gilead Sciences
Anthony Welters
Lead Indep. Independent
Chairman and CEO, CINQ Care
The board, organized
Board committees
1 standing committees. Audit and Compensation must be 100% independent under SEC rules; the rest vary.
Audit Committee
100% independent
Frequently Asked Questions
Who is the CEO of Gilead Sciences?
Daniel P. O’Day has served as Chairman and CEO since 2019.
What type of organizational structure does Gilead Sciences use?
Gilead uses a divisional structure organized around major therapeutic and commercial functions.
How many direct reports does Gilead Sciences's CEO have?
The CEO has three direct executive reports.
How has Gilead Sciences's leadership changed recently?
In late 2025, General Counsel Deborah Telman departed and Erin Burkhart was appointed SVP of Controllership.
Does Gilead Sciences have a COO?
No. Gilead does not currently have a Chief Operating Officer role.
Sources
- 8-K Filing, Nov 2025
- 8-K Filing, Aug 2025
- SEC EDGAR: Gilead Sciences, Inc. DEF 14A Proxy Statement
- SEC EDGAR: Gilead Sciences, Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Gilead Sciences, Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/gilead-sciences/MLA 9th
"Gilead Sciences, Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/gilead-sciences/. Accessed .Chicago 17
Creately. "Gilead Sciences, Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/gilead-sciences/.Original SEC source View on SEC ↗
Gilead Sciences, Inc.. DEF 14A. Filed 2026-03-20. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htmPermanent URL: https://creately.com/org-chart/fortune-500/gilead-sciences/ · last updated 2026-04-01